FDA Clears MiniMed Fit: What To Know About The New Tubeless Pump
Written by: Christine Fallabel
3 minute read
November 19, 2026
Medically reviewed by: Beyond Type 1 Clinical Team
On November 16th, the Food and Drug Administration (FDA) cleared the MiniMed Fit, the company’s first tubeless insulin pump that requires no charging or cartridge changes for up to seven days of wear.
This approval expands MiniMed’s insulin pump portfolio, joining the MiniMed 780G and the MiniMed Flex, which was cleared by the FDA earlier this year.
This is an exciting milestone both for MiniMed and for people living with diabetes. Many people with diabetes have been wanting more tubeless automated insulin delivery (AID) systems to choose from. AID systems connect an insulin pump with a continuous glucose monitor (CGM) and use an algorithm to adjust your insulin automatically based on your glucose levels.
With this approval, people with diabetes who use insulin now have three tubeless automated insulin delivery (AID) systems to choose from: Insulet’s Omnipod 5 system, the tubeless Tandem Mobi and now the MiniMed Fit.
What features does this new system offer?
The MiniMed Fit is designed to put people with diabetes in the driver’s seat of their care, with fewer diabetes-related interruptions. The system offers several key features to do just that, including:
- Up to seven days of continuous wear for fewer site changes
- 300-unit insulin capacity (other tubeless AID options hold 200 units)
- Automated insulin delivery using MiniMed’s SmartGuard technology, which adjusts insulin doses every five minutes
- Meal Detection Technology, which can deliver extra insulin when a meal dose (bolus) is missed or carbs are underestimated
- Access through the pharmacy channel, meaning you may be able to get it through your pharmacy benefit rather than as durable medical equipment (DME)
- Flexible wear locations, including the back of the arm, lower back, upper buttocks, abdomen and thigh
- Waterproof up to 8 feet for up to 1 hour and 45 minutes. Combined with the tubeless design, this gives you more flexibility for swimming, showering and playing sports or exercising.
- App control on compatible iOS and Android devices
- A choice of two all-in-one CGM sensors: MiniMed’s Simplera Sync, with up to seven days of wear, or Abbott’s Instinct, with up to 15 days of wear
“People with diabetes shouldn’t have to choose between the freedom of tubeless wear and the health outcomes they deserve,” said Que Dallara, chief executive officer of MiniMed. “MiniMed Fit brings the technology people trust from MiniMed into a tubeless design that fits their lives.”
Who is MiniMed Fit for?
The MiniMed Fit is cleared for people with type 1 diabetes and type 2 diabetes ages 7 and older.
This will be a great option for people who want fewer diabetes-related interruptions in their day-to-day life. With compatible CGMs that only need to be changed every seven or 15 days, your therapy can last longer without interruptions or site changes.
Additionally, the 300-unit capacity is 50% larger than any other tubeless option currently available. That makes this an especially appealing option for people who use more insulin or have insulin resistance.
When will the MiniMed Fit be available?
MiniMed is planning a small user experience launch in the fourth quarter of 2026, followed by a phased rollout for the U.S. commercial market in Spring 2027. That means most people won’t be able to get MiniMed Fit until next year. Details on cost and insurance coverage haven’t been shared yet.
Talk with your healthcare team if you’d like to learn more, or visit minimed.com/fit.
Looking for more support as you figure out which diabetes tech works best for you? Check out our Diabetes Technology Guide.
Related Resources
On Friday, the Food and Drug Administration (FDA) cleared the tubeless Tandem Mobi. This makes...
Read more
As a babysitter, you need to be prepared for anything. When you're babysitting a child...
Read more
Editor’s note: Insights shared in this guide come from Dr. Nuha El Sayed, MD, Interim...
Read more
